Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN), has highlighted the advocacy efforts the organization was involved in from the local level to the federal level.
Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN), has highlighted the advocacy efforts the organization was involved in from the local level to the federal level.
Transcript
What are some of the major advocacy efforts that ACS CAN has been involved in over the past year?
ACS CAN is a national organization and we work on the local level—sometimes as local as cities—the state level, and at the federal level. We have a presence in all 50 states and will advocate on things as small as smoke-free ordinances in a given city to things as large as healthcare reform, 21st Century Cures, things like that. We were very active in 21st Century Cures. That was a very bipartisan, open process, where the input of patient groups and all stakeholders was invited. And we provided testimony, lots of commentary on that. And we felt like we had a great opportunity to help shape and influence the legislation.
The other major issue that we really spent a lot of time on over the last 6 months is healthcare reform. The Affordable Care Act instituted a number of protections for cancer patients—things like abolishing lifetime caps, getting rid of preexisting condition exclusions, and community rating. So, as Congress decided to revisit a lot of the Affordable Care Act, and the way insurance is regulated and financed, we’ve stepped in and made sure that the provisions that are important to cancer patients, again things like lifetime caps and guaranteed issue, have maintained in any proposals going forward.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More